$IMUN Announces that Equity Partner, Cytocom, Inc., has Filed an Investigational New Drug Application to Conduct a Phase II Clinical Trial Evaluating CYTO-201 Treatment in COVID-19 Patients  #IMUN #stocks #investors #cytocom #drug #phase2 #COVIDー19